Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. (MYO) is a leader in developing wearable medical robotics that restore mobility for individuals with neuromuscular disorders. This page serves as the definitive source for official company announcements, providing stakeholders with timely updates on innovations shaping the orthotics industry.
Access curated press releases covering FDA milestones, product launches, and financial performance reports. Investors will find earnings disclosures and partnership announcements, while healthcare professionals can track clinical trial outcomes and insurance coverage expansions.
Our repository includes updates on Myomo’s myoelectric brace development, research collaborations with medical institutions, and regulatory progress across global markets. All content is sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page to monitor how MYO’s neuro-robotic solutions are advancing patient care while creating long-term value in the medical technology sector. Check regularly for developments impacting both clinical and investment communities.
Myomo, a wearable medical robotics company, announced preliminary revenues and operating metrics for Q2 2024. The company expects record quarterly revenues between $7.2 million and $7.4 million, a 92% to 97% increase from Q1 2024, and above the previous expectation of at least $5 million. Revenue units are anticipated to rise by 70% to 76% from Q1 2024. Payments from CMS and Medicare Advantage plans were faster than expected, aiding in the achievement of these figures. The company also recorded significant growth in pipeline additions, authorizations, and orders, each reaching record highs of approximately 550 and 210, respectively. Full financial results and future expectations will be disclosed in the second week of August 2024.
Myomo, a wearable medical robotics company, will present at the Sidoti Virtual Investor Conference on June 12-13, 2024. The company’s chairman and CEO, Paul Gudonis, alongside CFO David Henry, will lead the presentation and host one-on-one meetings with investors. The presentation is scheduled for 10:00 a.m. ET on June 12th and is accessible online. Investors can also request one-on-one meetings on both days. Registration for the event is free and available on Sidoti’s website.
Myomo, a wearable medical robotics company, reported financial results for Q1 2024. Highlights include $3.8 million in revenue, up 9% from Q1 2023, a record 275 patients in backlog, and 493 MyoPro candidates added to the pipeline. Gross margin decreased to 61.2%, and operating expenses increased by 24%. Net loss was $3.8 million. The company has a cash position of $11.0 million and expects to generate $28-30 million in revenue in 2024.
Myomo, Inc. (NYSE American: MYO) announced that Medicare Part B beneficiaries are receiving lump sum reimbursements for MyoPros, a wearable medical robotics offering increased functionality for those with neurological disorders and upper-limb paralysis. CMS has remitted payments based on published rates, effective April 1, 2024, through their regional contractors known as DME MACs. The company is pleased with the equitable access to this technology and the interest from clinical providers in the orthotics and prosthetics industry.
Myomo, a wearable medical robotics company, will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call on the same day with prepared remarks by its executives. Participants can pre-register for the call to gain immediate access.
FAQ
What is the current stock price of Myomo (MYO)?
What is the market cap of Myomo (MYO)?
